We are committed to addressing unmet need in women’s health and prostate cancer through purpose-driven science, empowering medicines, and transformative advocacy.
Our purpose is resolute and fueled by the opportunity to improve the lives of millions of patients, many impacted by diseases during their most productive years of life. Despite the significant burden of these diseases, patients do not have the options they deserve and need.
For too long, patients have suffered in the shadows. We are bringing this issue to the light and innovating for a brighter future.″
– Lynn Seely, MD, Chief Executive Officer
Become a part of our team and drive health forward
Our employees are motivated by a deep commitment to patient-centered innovation. We are always looking for passionate, hard-working individuals to join our fast-growing team. If this is you, we would love to hear from you.
Where we've come from
In April 2016, we entered into a license agreement with Takeda Pharmaceuticals International AG, in which we were granted an exclusive, worldwide license to develop and commercialize relugolix (excluding Japan and certain other Asian countries) and an exclusive license to develop and commercialize MVT-602 in all countries worldwide.
Takeda: Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience, and Rare Diseases. Takeda also makes targeted R&D investments in Plasma-Derived Therapies and Vaccines. Takeda is focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging its enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Takeda’s employees are committed to improving quality of life for patients and to working with its partners in health care in approximately 80 countries and regions.